New Global Licensing Agreement Announced
Boehringer Ingelheim and CDR-Life, Inc. are excited to unveil a new global licensing agreement centered around the development of CDR111, a groundbreaking antibody-based treatment for autoimmune diseases. This agreement is a significant step forward for both companies, building on a successful history of collaboration in the realm of retinal health and showcasing the unique capabilities of CDR-Life’s innovative antibody fragment platform.
Financial Implications and Partnership Potential
The deal signifies a potential for total payments reaching approximately USD 570 million. This includes around USD 48 million in upfront and near-term payments, as well as tiered royalties on future sales of the product. Such financial backing will support the extensive research and development required to bring CDR111 into clinical use.
Understanding CDR111 and Its Impact
CDR111 is categorized as a trispecific M-gager®, designed specifically to engage T-cells and selectively target B-cells. By effectively depleting these dysregulated B-cells, which are responsible for various autoimmune and inflammatory diseases such as lupus and multiple sclerosis, CDR111 aims to reset the immune system, offering hope for improved patient outcomes.
The Significance of Targeting B-cells
The role of B-cells in autoimmune conditions cannot be overstated. Their dysregulation can significantly contribute to the progression of these diseases. CDR111’s focused approach to targeting and depleting dysfunctional B-cells presents an innovative therapeutic avenue. This method holds promise for a wide array of indications, enhancing the potential for versatile applications in treatment.
Clinical Trials and Research Development
Progress in clinical trials is essential for CDR111. Currently, Boehringer has advanced an investigational antibody fragment that utilizes the technology licensed from CDR-Life. This fragment aims to protect vision in patients suffering from geographic atrophy, underscoring the companies’ commitment to effective medical solutions. The ongoing VERDANT™ Phase 2 trial is pivotal in assessing the efficiency and safety of this approach.
Remarks from Leadership
Christian Leisner, the CEO of CDR-Life, expresses enthusiasm regarding the expanded collaboration with Boehringer, describing it as a validation of their technology’s potential. “This agreement not only reflects our strong track record together but also our mutual commitment to address significant medical needs,” he stated.
Similarly, Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim, highlights the promise that CDR111 brings to autoimmune and inflammatory diseases. “This collaboration is a step towards expanding our pipeline with innovative solutions for serious autoimmune conditions,” she emphasized.
About the Companies Involved
Boehringer Ingelheim stands as a prominent biopharmaceutical company dedicated to addressing both human and animal health challenges. Established over 135 years ago, the company is renowned for its substantial investment in research and development. Their focus remains on creating innovative therapies that can significantly enhance the quality of life for patients globally.
CDR-Life specializes in developing targeted T-cell engagers for both solid tumors and autoimmune diseases. Their M-gager® platform is designed to deliver treatments against challenging targets with exceptional specificity. As they advance through clinical stages, CDR-Life aims to revolutionize therapy options available to those affected by serious medical conditions.
Contact Information
Boehringer Ingelheim Contact: Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
Email: press@boehringer-ingelheim.com
CDR-Life Contacts:
Media: Lauren Arnold
Email: Lauren@lacommunications.net
Investors: Christian Leisner, CEO, CDR-Life Inc.
Email: Christian.leisner@cdr-life.com
Frequently Asked Questions
What is CDR111?
CDR111 is an antibody-based trispecific M-gager® designed to target and deplete dysregulated B-cells in autoimmune diseases.
What are the financial terms of the agreement?
The agreement could lead to total payments of approximately USD 570 million, including upfront and near-term payments of about USD 48 million.
What is the significance of targeting B-cells?
Dysregulated B-cells contribute to many autoimmune diseases; depleting them can help reset the immune system.
Where is CDR111 currently being tested?
CDR111 is in clinical development, and its progress is linked to the VERDANT Phase 2 trial aimed at evaluating its efficacy.
What companies are involved in this collaboration?
The collaboration involves Boehringer Ingelheim and CDR-Life, both of which are committed to advancing medical therapies for significant health issues.
